AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36067452 — intervention group
Group type: COMPARATOR
Intervention: Later-line anti-EGFR-antibody therapy
Number of subjects: 292
Study 34407860 — intervention group
Group type: EXPERIMENTAL
Intervention: Focal therapy (specifics not provided)
Number of subjects: 0
Study 34407860 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 32427122 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention (6 sessions of 60 minutes each, starting from week 26 to 37 of pregnancy)
Number of subjects: 84
Study 32427122 — intervention group
Group type: COMPARATOR
Intervention: Control group (no yoga intervention)
Number of subjects: 84
Study 33285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) with a median dose of 33.3 Gy (range: 27 to 54 Gy) in 5 fractions
Number of subjects: 128
Study 33285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT) followed by sorafenib
Number of subjects: 128
Study 33285195 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic body radiation therapy (SBRT)
Number of subjects: 128
Study 32272505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that randomized or mandated hormone therapy
Number of subjects: 131
Study 32272505 — intervention group
Group type: EXPERIMENTAL
Intervention: Trials that did not randomize or mandate endocrine therapy
Number of subjects: 131
Study 35525865 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grains diet (75% of total carbohydrates)
Number of subjects: 248
Study 35525865 — intervention group
Group type: COMPARATOR
Intervention: Refined grains diet (75% of total carbohydrates)
Number of subjects: 248
Study 32946820 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg twice daily
Number of subjects: 502
Study 32946820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 36086703 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii CNCM I-745
Number of subjects: 317
Study 36086703 — intervention group
Group type: COMPARATOR
Intervention: Bacillus clausii
Number of subjects: 317
Study 36086703 — intervention group
Group type: EXPERIMENTAL
Intervention: Both probiotics
Number of subjects: 317
Study 34351356 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (CCRT) with S-1
Number of subjects: 298
Study 34351356 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy (RT) alone
Number of subjects: 298
Study 34426474 — intervention group
Group type: EXPERIMENTAL
Intervention: Mendelian randomization (MR)
Number of subjects: 0
Study 34044407 — intervention group
Group type: EXPERIMENTAL
Intervention: Divaza
Number of subjects: 124
Study 34044407 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study 33032234 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy with systemic antibiotics (PT1 group)
Number of subjects: 90
Study 33032234 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy without antibiotics (PT2 group)
Number of subjects: 90
Study 33032234 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no periodontal therapy
Number of subjects: 90
Study 33032234 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups (PT1 and PT2)
Number of subjects: 90
Study 33032234 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 90
Study 34420873 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal approach
Number of subjects: 20
Study 34420873 — intervention group
Group type: COMPARATOR
Intervention: Both approaches
Number of subjects: 20
Study 34080247 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and lifestyle modification intervention (n = 59)
Number of subjects: 121
Study 34080247 — intervention group
Group type: COMPARATOR
Intervention: Usual care (n = 62)
Number of subjects: 121
Study 34080247 — intervention group
Group type: EXPERIMENTAL
Intervention: Health and lifestyle modification intervention
Number of subjects: 121
Study 32811843 — intervention group
Group type: EXPERIMENTAL
Intervention: ADV7103 (alkalising agent) at doses of 1.44 meq/kg twice a day
Number of subjects: 16
Study 32811843 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 35427760 — intervention group
Group type: EXPERIMENTAL
Intervention: 30‐day smartphone‐based mindfulness meditation training
Number of subjects: 0
Study 35427760 — intervention group
Group type: COMPARATOR
Intervention: Problem‐solving control program
Number of subjects: 0
Study 33464412 — intervention group
Group type: EXPERIMENTAL
Intervention: MI of ankle plantarflexion (MI-PF)
Number of subjects: 23
Study 33464412 — intervention group
Group type: EXPERIMENTAL
Intervention: MI of ankle dorsiflexion (MI-DF)
Number of subjects: 23
Study 33464412 — intervention group
Group type: COMPARATOR
Intervention: MI of ankle dorsiflexion (MI-DF) after 10 min practice
Number of subjects: 23
Study 33464412 — intervention group
Group type: COMPARATOR
Intervention: Resting condition
Number of subjects: 23
Study 32938447 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropalliative care intervention
Number of subjects: 151
Study 36153625 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous lidocaine (1.5 mg/kg bolus followed by 4 mg/kg/h continuous infusion)
Number of subjects: 300
Study 36153625 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (same volumes as lidocaine)
Number of subjects: 300
Study 35718070 — intervention group
Group type: EXPERIMENTAL
Intervention: GEADS (AI-assisted diagnosis system)
Number of subjects: 11
Study 33599356 — intervention group
Group type: EXPERIMENTAL
Intervention: E6011 (anti-fractalkine antibody) 2, 5, 10, and 15 mg/kg intravenously every 2 weeks during the 12-week multiple ascending dose phase.
Number of subjects: 28
Study 33289953 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS‐16C3F 1.8 mg/kg every 3 weeks
Number of subjects: 133
Study 33289953 — intervention group
Group type: COMPARATOR
Intervention: Axitinib 5 mg twice daily (starting dose)
Number of subjects: 133
Study 33289953 — intervention group
Group type: EXPERIMENTAL
Intervention: AGS‐16C3F
Number of subjects: 133
Study 33289953 — intervention group
Group type: COMPARATOR
Intervention: Axitinib
Number of subjects: 133
Study 33104490 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Transfer to Angio-Suite (DTAS)
Number of subjects: 0
Study 33104490 — intervention group
Group type: COMPARATOR
Intervention: Computed Tomography-Transit (CTT)
Number of subjects: 0
Study 35428315 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical Decision Support System (CDSS)
Number of subjects: 498
Study 35428315 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 498
Study 33922334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group with visual and oral instructor prompts to stand
Number of subjects: 48
Study 33922334 — intervention group
Group type: COMPARATOR
Intervention: Control group with no prompts
Number of subjects: 48
Study 33922334 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 48
Study 32807208 — intervention group
Group type: EXPERIMENTAL
Intervention: Protac Ball Blanket™ (PBB)
Number of subjects: 45
Study 32807208 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 45
Study 33162389 — intervention group
Group type: EXPERIMENTAL
Intervention: Vascular ultrasound examination in the carotid and femoral arteries assessing 12 territories, combined with clinical, anthropometric, lifestyle, and biochemical parameters.
Number of subjects: 8330
Study 32999269 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus (GDM)
Number of subjects: 300
Study 36278178 — intervention group
Group type: EXPERIMENTAL
Intervention: Brazilian Organic Propolis (BOP)
Number of subjects: 60
Study 36278178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 32954688 — intervention group
Group type: EXPERIMENTAL
Intervention: Sina curcumin capsules 80 mg
Number of subjects: 48
Study 32954688 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 32954688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study 35464292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous dasiglucagon (doses ranged from 0.03 mg to 1.5 mg)
Number of subjects: 60
Study 35464292 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dasiglucagon (0.6 mg)
Number of subjects: 60
Study 35464292 — intervention group
Group type: COMPARATOR
Intervention: Intravenous placebo
Number of subjects: 60
Study 34266452 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin, Atorvastatin, Nicorandil (Aspirin 325 mg starting dose, 75 mg once daily; Atorvastatin 40 mg starting dose, 40 mg once daily; Nicorandil 10 mg starting dose, 5 mg twice daily) plus conventional therapy
Number of subjects: 396
Study 34266452 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy only
Number of subjects: 396
Study 36397132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine, administered in three monthly rounds at the beginning of the malaria transmission season.
Number of subjects: 32
Study 36397132 — intervention group
Group type: EXPERIMENTAL
Intervention: Mass drug administration (MDA) with ivermectin (IVM) and dihydroartemisinin-piperaquine.
Number of subjects: 32
Study 36397132 — intervention group
Group type: COMPARATOR
Intervention: Mosquitoes fed on blood from IVM-treated individuals.
Number of subjects: 32
Study 35605609 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (dose titrated from 0.25 mg/d to 1.0 mg/d)
Number of subjects: 40
Study 35605609 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 33223140 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 22
Study 33223140 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 32863329 — intervention group
Group type: EXPERIMENTAL
Intervention: Hybrid Training System (HTS)
Number of subjects: 18
Study 35750681 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI362 (3.0 mg, 4.5 mg or 6.0 mg)
Number of subjects: 43
Study 35750681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide (1.5 mg)
Number of subjects: 43
Study 35750681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43
Study 35750681 — intervention group
Group type: EXPERIMENTAL
Intervention: IBI362
Number of subjects: 43
Study 35611762 — intervention group
Group type: EXPERIMENTAL
Intervention: 52% low-sodium salt and DASH diet
Number of subjects: 61
Study 35611762 — intervention group
Group type: COMPARATOR
Intervention: Normal salt and DASH diet
Number of subjects: 61
Study 34740373 — intervention group
Group type: EXPERIMENTAL
Intervention: HENRY plus the implementation optimisation intervention
Number of subjects: 20
Study 34740373 — intervention group
Group type: COMPARATOR
Intervention: HENRY alone (control)
Number of subjects: 20
Study 32674447 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical dexamethasone
Number of subjects: 76
Study 32674447 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical clobetasol
Number of subjects: 76
Study 32674447 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical budesonide
Number of subjects: 76
Study 34785390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients who reported Spanish as their primary language
Number of subjects: 295
Study 34785390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients with diabetes
Number of subjects: 295
Study 34785390 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline autonomy scores in patients with depressive symptoms
Number of subjects: 295
Study 34785390 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy scores of Non-Hispanic White participants compared to Non-Hispanic Black participants
Number of subjects: 295
Study 33632194 — intervention group
Group type: EXPERIMENTAL
Intervention: Game jam intervention to create an educational game on cultural safety
Number of subjects: 531
Study 33632194 — intervention group
Group type: COMPARATOR
Intervention: Standard lesson plus an interactive workshop on cultural safety
Number of subjects: 531
Study 33632194 — intervention group
Group type: EXPERIMENTAL
Intervention: Game jam intervention
Number of subjects: 531
Study 32550229 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-Promoting Lifestyle Education Intervention (HPLEI) for 8 weeks
Number of subjects: 72
Study 32550229 — intervention group
Group type: COMPARATOR
Intervention: Control group (no planned education programme)
Number of subjects: 72
Study 35533885 — intervention group
Group type: EXPERIMENTAL
Intervention: Abstinence-contingent financial incentives (FI)
Number of subjects: 0
Study 35533885 — intervention group
Group type: EXPERIMENTAL
Intervention: Pooled trials of abstinence-contingent financial incentives (FI)
Number of subjects: 0
Study 35533885 — intervention group
Group type: COMPARATOR
Intervention: Control conditions (Best Practices alone and noncontingent payments)
Number of subjects: 0
Study 35814305 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal Shock Wave Therapy (ESWT) with oral drug treatment
Number of subjects: 143
Study 35814305 — intervention group
Group type: COMPARATOR
Intervention: Oral drug treatment only (Control)
Number of subjects: 143
Study 32223331 — intervention group
Group type: EXPERIMENTAL
Intervention: APRI
Number of subjects: 405
Study 32223331 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibro-α Scores
Number of subjects: 405
Study 32223331 — intervention group
Group type: EXPERIMENTAL
Intervention: GUCI
Number of subjects: 405
Study 32223331 — intervention group
Group type: EXPERIMENTAL
Intervention: King Score
Number of subjects: 405
Study 35038723 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/kg maintenance dose every 3 weeks
Number of subjects: 142
Study 35038723 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0 g/kg maintenance dose every 3 weeks
Number of subjects: 142
Study 35038723 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0 g/kg maintenance dose every 3 weeks
Number of subjects: 142
Study 35038723 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction dose alone
Number of subjects: 142
Study 35038723 — intervention group
Group type: COMPARATOR
Intervention: 0.5 g/kg maintenance dose
Number of subjects: 142
Study 35038723 — intervention group
Group type: COMPARATOR
Intervention: 1.0 g/kg maintenance dose
Number of subjects: 142
Study 35038723 — intervention group
Group type: COMPARATOR
Intervention: 2.0 g/kg maintenance dose
Number of subjects: 142
Study 34078307 — intervention group
Group type: EXPERIMENTAL
Intervention: Hope-oriented group counseling
Number of subjects: 60
Study 34078307 — intervention group
Group type: COMPARATOR
Intervention: Routine care (control)
Number of subjects: 60
Study 32812177 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (n = 41)
Number of subjects: 89
Study 32812177 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 47)
Number of subjects: 89
Study 34153943 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies with statistically significant OS endpoints (56 trials)
Number of subjects: 362
Study 34153943 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies with non-significant OS endpoints (131 trials)
Number of subjects: 362
Study 34153943 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental therapies with PRS endpoints (total analyzed: 216)
Number of subjects: 362
Study 32375151 — intervention group
Group type: EXPERIMENTAL
Intervention: Robo-Cob technique
Number of subjects: 25
Study 32375151 — intervention group
Group type: COMPARATOR
Intervention: CELL technique (control)
Number of subjects: 25
Study 35362709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical approach (Method for surgical treatment of odontogenic oral phlegmon of mouth floor with partial dissection of sublingual‐submandibular sac)
Number of subjects: 86
Study 35362709 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified surgical approach
Number of subjects: 86
Study 33627633 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched chain amino acids (BCAA) and tyrosine
Number of subjects: 173
Study 33627633 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaine and choline
Number of subjects: 173
Study 33627633 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical model including metabolite factors
Number of subjects: 173
Study 33627633 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline levels of metabolites in BCAA and TMAO-microbiome-related pathways
Number of subjects: 173
Study 34260606 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitively engaging active breaks
Number of subjects: 141
Study 34260606 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 141
Study 32511803 — intervention group
Group type: EXPERIMENTAL
Intervention: D1 Now intervention (support-worker, interactive messaging system, agenda setting tool)
Number of subjects: 0
Study 32511803 — intervention group
Group type: COMPARATOR
Intervention: Usual care control arm
Number of subjects: 0
Study 35301018 — intervention group
Group type: EXPERIMENTAL
Intervention: Video-based anticipatory guidance at well-child visits
Number of subjects: 0
Study 33394691 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-vessel CTO PCI
Number of subjects: 1000
Study 33394691 — intervention group
Group type: COMPARATOR
Intervention: Multivessel PCI
Number of subjects: 1000
Study 32175988 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained at 60 to 65 mmHg
Number of subjects: 22
Study 32175988 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained at 80 to 85 mmHg
Number of subjects: 22
Study 32175988 — intervention group
Group type: EXPERIMENTAL
Intervention: MAP maintained at 70 to 75 mmHg
Number of subjects: 22
Study 36477637 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-suction group
Number of subjects: 80
Study 36477637 — intervention group
Group type: COMPARATOR
Intervention: Open-suction group
Number of subjects: 80
Study 35606020 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 pandemic and associated lockdown measures
Number of subjects: 437
Study 34667852 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin (BT) therapy
Number of subjects: 22
Study 34667852 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 34751780 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 510
Study 34751780 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 510
Study 33325799 — intervention group
Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder) single doses of 0.2-2.4 mg
Number of subjects: 32
Study 33325799 — intervention group
Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder) repeated doses of up to 2.4 mg q4h for four doses daily for 9 days
Number of subjects: 32
Study 33325799 — intervention group
Group type: EXPERIMENTAL
Intervention: RT234 (vardenafil inhalation powder)
Number of subjects: 32
Study 33325799 — intervention group
Group type: COMPARATOR
Intervention: 20 mg vardenafil tablets (Levitra®)
Number of subjects: 32
Study 34187823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme (10-session mindfulness-based and acceptance-based group programme followed by 12 weeks of physical activity counselling)
Number of subjects: 170
Study 34187823 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (no treatment or any other treatment of their choice)
Number of subjects: 170
Study 34187823 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent rehabilitation programme
Number of subjects: 170
Study 34187823 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 170
Study 32611865 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel herbal anesthetic gel
Number of subjects: 30
Study 32611865 — intervention group
Group type: COMPARATOR
Intervention: 2% lignocaine gel
Number of subjects: 30
Study 34993962 — intervention group
Group type: EXPERIMENTAL
Intervention: Recalling a special moment from high school
Number of subjects: 0
Study 34993962 — intervention group
Group type: COMPARATOR
Intervention: Recalling an ordinary event from high school
Number of subjects: 0
Study 33783506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral doxycycline
Number of subjects: 87
Study 33783506 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular procaine G penicillin
Number of subjects: 87
Study 32866148 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental Group (EG) - Core muscle training
Number of subjects: 16
Study 32866148 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No core muscle training
Number of subjects: 16
Study 35553371 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval Exercise (IE)
Number of subjects: 44
Study 35553371 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated Exercise (AE)
Number of subjects: 44
Study 35553371 — intervention group
Group type: COMPARATOR
Intervention: Continuous Exercise (CE)
Number of subjects: 44
Study 36121357 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive care management
Number of subjects: 131
Study 36121357 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (control)
Number of subjects: 131
Study 32926603 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamfetamine dimesylate (LDX) starting at 20 mg/d and titrated to a maximum of 70 mg/d
Number of subjects: 35
Study 32926603 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Parent Training (BPT)
Number of subjects: 35
Study 35930284 — intervention group
Group type: EXPERIMENTAL
Intervention: ETC-assigned facilities
Number of subjects: 6062
Study 33513650 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic plasma exchange (TPE) in septic shock
Number of subjects: 0
Study 33513650 — intervention group
Group type: EXPERIMENTAL
Intervention: High volume TPE in acute liver failure
Number of subjects: 0
Study 33513650 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy containing anticoagulation, corticosteroids, and TPE or intravenous immunoglobulin in CAPS
Number of subjects: 0
Study 33513650 — intervention group
Group type: EXPERIMENTAL
Intervention: TPE for thyrotoxic storm
Number of subjects: 0
Study 33479025 — intervention group
Group type: COMPARATOR
Intervention: Arm A (6MHP + IFA)
Number of subjects: 48